Completed PHASE2 INTERVENTIONAL 8-arm NCT01817530

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Sponsor: AbbVie

Conditions Heavy Uterine Bleeding Uterine Fibroids

Interventions 0.5 mg estradiol / 0.1 mg norethindrone acetate 1 mg estradiol / 0.5 mg norethindrone acetate E2/NETA placebo Elagolix Elagolix placebo

Updated 9 times since 2017 Last updated: Jul 7, 2020 Started: Apr 8, 2013 Primary completion: Jun 30, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Heavy Uterine Bleeding and Uterine Fibroids, this trial is completed. The trial is conducted by AbbVie and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2020 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Aug 2020 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Mar 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Mar 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.